Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	SEK 0.4705	-49.79%	14,424,697
10/09/26	SEK 0.9370	+3.31%	1,107,793
09/09/26	SEK 0.9070	-5.52%	2,702,989
08/09/26	SEK 0.9600	+6.79%	2,513,673
07/09/26	SEK 0.8990	+9.23%	2,544,746

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 02:00:00 12/09/26 am AEST			5-day change	1st Jan Change
0.4705 ^SEK	-49.79%		-42.83%	-43.24%

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW

Market Cap	95.34M 9.84M 8.48M 8.03M 7.28M 13.65M 940M 13.72M 36.66M 478M 36.95M 36.14M 1.51B	P/E 2026 *	-1.74x	P/E 2027 *	-1.24x
Enterprise Value	79.34M 8.19M 7.06M 6.68M 6.06M 11.36M 782M 11.42M 30.51M 398M 30.75M 30.08M 1.26B	EV / Sales 2026 *	2.53x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
CBOE		Real-time

12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
25/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
11/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
11/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ

1 day	-49.79%
1 week	-42.83%
Current month	-41.19%
1 month	-53.04%
3 months	-3.19%
6 months	-48.69%
Current year	-43.24%

1 week	0.47	1.04
1 month	0.47	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-49.79%	-42.83%	-62.24%	-85.32%	9.84M
LONZA GROUP AG	-0.71%	-6.35%	-2.99%	+9.37%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+520.30%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.85%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+73.19%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+108.58%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.78%	+30.20%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+36.66%	13.28B
Average	-4.54%	-7.16%	+48.96%	+83.73%	26.48B
Weighted average by Cap.	+0.41%	-3.50%	+74.56%	+124.85%

	2026 *	2027 *
Net sales	31.35M 3.24M 2.79M 2.64M 2.39M 4.49M 309M 4.51M 12.06M 157M 12.15M 11.88M 497M	-
Net income	-4.45M -459K -396K -375K -340K -637K -43.88M -640K -1.71M -22.32M -1.72M -1.69M -70.54M	-77M -7.95M -6.85M -6.48M -5.88M -11.02M -759M -11.08M -29.61M -386M -29.85M -29.19M -1.22B
Net Debt	-16M -1.65M -1.42M -1.35M -1.22M -2.29M -158M -2.3M -6.15M -80.26M -6.2M -6.07M -254M	-19M -1.96M -1.69M -1.6M -1.45M -2.72M -187M -2.73M -7.31M -95.31M -7.36M -7.2M -301M